Dopamine replacement therapy modulates dopa decarboxylase, prolactin and AOC3 levels in Parkinson’s disease
Objective: Investigate the impact of dopamine replacement therapy (DRT) on the serum and CSF proteome of people with Parkinson’s disease (PwPD). Background: New high-throughput technologies…Nutritional Parameter Changes in Parkinson’s Disease Patients Receiving Continuous Subcutaneous Infusion of Foslevodopa-Foscarbidopa
Objective: This study aims to assess changes in nutritional parameters in patients with Parkinson’s disease (PD) undergoing continuous subcutaneous infusion (CSCI) of foslevodopa-foscarbidopa. Background: Device-aided…Effectiveness of Opicapone Added to Different Levodopa Doses and LEDDs in Parkinson’s Disease: Post-Hoc Analysis of the ADOPTION Trials
Objective: To assess the efficacy of opicapone 50 mg, compared to an additional 100 mg dose of levodopa, in reducing OFF-time in Parkinson’s disease (PD)…Digital measurement of ocular microtremor in Parkinson’s Disease: Analytical and clinical validation
Objective: This pilot study examined the analytical and clinical validation of OMT measurement via the iTremor ONE device in PwPD. Background: Ocular microtremor (OMT) is…Incidence and Determinants of Nodule formation in continuous subcutaneous Foslevodopa/Foscarbidopa Infusion therapy.
Objective: This study aims to evaluate the incidence of subcutaneous (SC) nodules in Parkinson’s patients treated with continuous 24-hour SC infusion of foslevodopa/foscarbidopa (LDp/CDp) and…Intravenous L-dopa Administration in PD and DLB Patients with Oral Intake Difficulties: Current Status and Challenges
Objective: Investigation of efficacy and challenges of intravenous L-dopa therapy as an alternative treatment for PD patients and those with DLB who experience difficulty with…Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion Foslevodopa/Foscarbidopa Therapy
Objective: This study aims to identify clinical predictors of continuous subcutaneous infusion (CSCI)-induced psychosis to understand its potential mechanisms and evaluate predictive measures for its…Pharmacokinetic Analysis of Subcutaneous Levodopa/Carbidopa Delivery With ND0612
Objective: To (i) use a population pharmacokinetic (PK) model to compare predicted levodopa PK parameters when levodopa is delivered as investigational ND0612, as oral immediate-release…A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations
Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…Utilizing the Levodopa Challenge Test to Clarify Clinical Complaints Following Levodopa Administration: A Case Series
Objective: To characterize subjective clinical complaints reported by patients with Parkinson's Disease (PD) following levodopa administration and evaluate the utility of the levodopa challenge test…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 62
- Next Page »